The proposed sale is small relative to the company's market cap and the insider's likely total holdings. No material impact expected. Monitor for any subsequent Form 4 filings to confirm whether the sale was executed.
GMAB drugs
GMAB drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK BELOW ENTRY AT T+1- T+0 · Nov 10 $54.07entry
- T+1 · 6d ago −0.37%α −1.69% · $53.87
- T+4 · todayOpen
- T+5 · in 7h Pending
- T+20 · in 22d Pending
- T+60 · in 3mo Pending
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Judith V. Klimovsky, an officer of Genmab, filed a Form 144 notice of intent to sell 1,265 shares of common stock, with an estimated aggregate market value of approximately $704,327. The shares were acquired through stock awards in 2021 and 2023. The sale is relatively small relative to the company's $33.5B market cap and appears to be a routine insider transaction.
Key Facts
- Insider Judith V. Klimovsky (Officer) filed Form 144 to sell 1,265 shares of Genmab common stock.
- Estimated aggregate market value of the proposed sale is approximately $704,327.
- Shares were acquired via stock awards on 01/06/2021 (365 shares) and 01/02/2023 (900 shares) as compensation.
- The sale is planned for or around 11/10/2026.
- The filing is an advance notice of intent to sell; the actual sale may not occur.
Financial Impact
Proposed sale of 1,265 shares valued at ~$704,327, representing less than 0.01% of Genmab's market cap.
Risk Factors
- Insider sale may signal personal liquidity needs rather than a negative view on the company.
- Form 144 is an intent to sell; the sale may not be completed.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (Primary) | 0001959173-26-007899 |
| Document: 0001959173-26-007899-index.html | 0001959173-26-007899 |
| Document: 0001959173-26-007899.txt | 0001959173-26-007899 |
Track record
31 reports on GMAB
3 of 5 bullish or bearish reports moved the stock their way by T+20. Best: +91.28% at T+60 after the Aug 6, 2026 report. 5 of 7 went positive at some point.
Filters
- Nov 16, 2026today SC 13G/A Neutral 3/10 Entry $52.12 Now $51.57 −1.06% settles Dec 15
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 12, 20264d ago 6-K Neutral 2/10 Entry $51.74 Now $51.57 −0.33% settles Dec 11
- Nov 10, 20266d ago 6-K Neutral 2/10 Entry $53.87 Now $51.57 −4.27% settles Dec 10
- Nov 10, 20266d ago 144 Neutral 2/10 Viewing Entry $54.07 Now $51.57 −4.62% settles Dec 9
- Nov 5, 202611d ago 6-K Neutral 5/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Nov 4, 202612d ago Institutional Cluster Neutral 2/10 Entry $52.74 Now $51.57 −2.22% settles Dec 4
- Oct 28, 202619d ago 6-K Bullish 6/10 Entry $57.29 Now $51.57 −9.98% settles Nov 25
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers